Nektar to pursue anticancer alone as positive Phase II data keep rolling in
This article was originally published in Scrip
Nektar Therapeutics has decided to continue developing the cancer treatment NKTR-102 by itself instead of seeking a partner, with the potential of huge upside if the drug makes it to market.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.